Investors in Surgery Partners (NASDAQ:SGRY) Have Unfortunately Lost 53% Over the Last Three Years
Worst Performing Stocks for Tax Loss Selling – Wolfe
BofA Securities Initiates Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $30
Surgery Partners Reinstated With a Buy at BofA
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
Surgery Partners, Inc. (NASDAQ:SGRY) Is Expected To Breakeven In The Near Future
Returns On Capital At Surgery Partners (NASDAQ:SGRY) Have Hit The Brakes
